glp-1 drugs competitive intelligence 2025 trends 2025: real-world data, patient outcomes & future therapies GLP-1 Pipeline Update: August 2025

Sorry, not the earthquake hithennae

37 FGF19 FGF19 is a regulator of bile acid synthesis produced by intestinal cells after meals in response to farnesoid X receptor (FXR) stimulation

The temporary nature of results combined with the need for continuous treatment represents a significant consideration for those evaluating glutathione IV therapy for skin brightening purposes

Convenient form - the preparation available in a powder form ensures a trouble-free supply of the dietary supplement and will be great for people who have difficulty swallowing tablets

Known PK literature gaps 11

Our results suggest that implementing GLP-1RAs therapy could help prevent WR after bariatric surgery